Short Interest in Gossamer Bio Inc (NASDAQ:GOSS) Rises By 21.0%

Share on StockTwits

Gossamer Bio Inc (NASDAQ:GOSS) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 4,380,000 shares, a growth of 21.0% from the December 15th total of 3,620,000 shares. Based on an average daily volume of 593,000 shares, the days-to-cover ratio is presently 7.4 days. Currently, 10.2% of the shares of the stock are short sold.

Several research firms recently weighed in on GOSS. Bank of America began coverage on shares of Gossamer Bio in a report on Tuesday, December 3rd. They issued a “buy” rating and a $32.00 price objective for the company. Zacks Investment Research raised shares of Gossamer Bio from a “sell” rating to a “hold” rating in a report on Tuesday. Berenberg Bank began coverage on shares of Gossamer Bio in a report on Wednesday, October 30th. They issued a “buy” rating and a $31.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective (down previously from $34.00) on shares of Gossamer Bio in a report on Tuesday, December 17th. Finally, ValuEngine downgraded shares of Gossamer Bio from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $28.29.

In related news, insider Jakob Dupont sold 40,000 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $15.00, for a total value of $600,000.00. Following the completion of the sale, the insider now owns 1,994 shares of the company’s stock, valued at $29,910. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 23.30% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co NY acquired a new position in shares of Gossamer Bio in the 3rd quarter valued at about $239,000. Redmile Group LLC increased its holdings in Gossamer Bio by 4.8% in the third quarter. Redmile Group LLC now owns 260,500 shares of the company’s stock worth $4,374,000 after buying an additional 11,900 shares during the last quarter. Barclays PLC acquired a new position in Gossamer Bio in the third quarter worth approximately $1,447,000. California State Teachers Retirement System increased its holdings in Gossamer Bio by 116.9% in the third quarter. California State Teachers Retirement System now owns 66,823 shares of the company’s stock worth $1,122,000 after buying an additional 36,021 shares during the last quarter. Finally, State Street Corp increased its holdings in Gossamer Bio by 115.3% in the third quarter. State Street Corp now owns 747,938 shares of the company’s stock worth $12,558,000 after buying an additional 400,491 shares during the last quarter. Institutional investors own 61.47% of the company’s stock.

Shares of GOSS opened at $14.67 on Wednesday. The company has a market capitalization of $933.12 million and a price-to-earnings ratio of -0.65. Gossamer Bio has a fifty-two week low of $13.12 and a fifty-two week high of $27.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 13.64 and a quick ratio of 13.64. The business’s 50-day moving average is $19.39 and its 200-day moving average is $19.70.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Tuesday, November 12th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.10). Equities research analysts expect that Gossamer Bio will post -3.05 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

See Also: What moving averages are used to define a golden cross?

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.